Showing results (31-40 of 61) with videos related to

Sort By:
Pageof 7
World Journal of Clinical Oncology|May 2, 2020
Prognostic importance of lymph node yield after curative resection of gastroenteropancreatic neuroendocrine tumoursJaseela Chiramel, Rose Almond, Astrid Slagter, et al.
Clinical and Experimental Medicine|January 21, 2026
Maintaining oxaliplatin therapy after hypersensitivity reactions: real-world experience with a desensitisation protocolEleftherios Christodoulis, Panagiotis J Vlachostergios, Jacqueline Connell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 3, 2021
Impact of Pembrolizumab Versus Chemotherapy as Second-Line Therapy for Advanced Esophageal Cancer on Health-Related Quality of Life in KEYNOTE-181Antoine Adenis, Amit S Kulkarni, Gustavo C Girotto, et al.
JAMA Oncology|October 11, 2019
Efficacy and Safety of Trifluridine/Tipiracil Treatment in Patients With Metastatic Gastric Cancer Who Had Undergone Gastrectomy: Subgroup Analyses of a Randomized Clinical TrialDavid H Ilson, Josep Tabernero, Aliaksandr Prokharau, et al.
World Journal of Gastroenterology|October 30, 2019
Retrospective study on mixed neuroendocrine non-neuroendocrine neoplasms from five European centresMelissa Frizziero, Xin Wang, Bipasha Chakrabarty, et al.
BMJ Open|February 8, 2020
NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC)Zoe Craig, Jayne Swain, Emma Batman, et al.
Cancers|August 27, 2021
Is the Morphological Subtype of Extra-Pulmonary Neuroendocrine Carcinoma Clinically Relevant?Melissa Frizziero, Alice Durand, Rodrigo G Taboada, et al.
The Lancet. Oncology|December 17, 2013
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trialHugo E R Ford, Andrea Marshall, John A Bridgewater, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|March 13, 2021
Trifluridine/tipiracil in patients with metastatic gastroesophageal junction cancer: a subgroup analysis from the phase 3 TAGS studyWasat Mansoor, Hendrik-Tobias Arkenau, Maria Alsina, et al.
The Lancet. Oncology|March 28, 2017
Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 studyPeter C Thuss-Patience, Manish A Shah, Atsushi Ohtsu, et al.
Pageof 7